Acetazolamide Side Effects and Management

Introduction to Side Effects

Acetazolamide causes common and dose-dependent side effects, with paraesthesias occurring in nearly half of patients, along with dysgeusia, polyuria, fatigue, and potentially serious electrolyte imbalances that require monitoring 1, 2

Paraesthesias are the most frequent side effect, affecting approximately 1 in 2-3 patients, with risk increasing significantly at higher doses 1, 2
Dysgeusia occurs in approximately 1 in 18 patients, with dose-dependent risk 1, 2
Tinnitus is a recognized adverse effect 1, 2
Cognitive slowing and depression can occur, particularly concerning for patients requiring mental acuity 1, 2
Nausea and vomiting are well-documented side effects 1, 2
Diarrhea occurs with increased frequency 1, 2
Fatigue occurs in approximately 1 in 11 patients, with a trend toward dose-dependence 1, 2

Renal stones occur rarely but are a recognized complication 1, 2
Development of acidotic state can occur, particularly in overdose situations 1, 2

In clinical practice, 48% of patients discontinue acetazolamide at mean doses of 1.5 g/day due to side effects, while only 44% tolerate the maximum 4 g/day dose 1, 2
Pregnancy is a contraindication due to potential teratogenic risks 1

Start low (250-500 mg twice daily) and titrate gradually to minimize initial side effect burden 1, 2
Acetazolamide has not been shown effective for headache treatment alone in conditions like idiopathic intracranial hypertension 1, 2

The European Respiratory Society suggests using acetazolamide only in research settings for Obstructive Sleep Apnea (OSA), as there is no approved label for OSA, and it can reduce sleep apnea intensity (AHI) by up to 45% in unselected groups 3, 4
Acetazolamide improves oxygen saturation and reduces oxygen desaturation index in patients with OSA 5
The European Respiratory Society guidelines recommend using acetazolamide for OSA in research settings only, with no documented effect on excessive daytime sleepiness 3
Studies show improved nocturnal oxygen saturation and reduced blood pressure increases at high altitude with acetazolamide use 3, 6

The dose range for acetazolamide in OSA trials is 36-1000 mg daily, with treatment periods up to 3 months 3
For Idiopathic Intracranial Hypertension/Pseudotumor Cerebri, the initial dose is 25 mg/kg/day, titrated upward until clinical response (maximum 100 mg/kg/day) 7
In pediatric use for pseudotumor cerebri, a reduced dose of 25 mg/m² is recommended 7

Acetazolamide use is associated with vertigo and unpleasant taste 3
Electrolyte imbalances, particularly hypokalemia, are a serious adverse effect of acetazolamide 7
Acetazolamide may reduce blood pressure, particularly at high altitude (systolic reduction of 7-10 mmHg) 3, 6

Acetazolamide increases resting ventilation and augments central respiratory drive through metabolic acidosis, shifting the CO2 ventilatory response curve leftward, according to the British Journal of Pharmacology 8

The American College of Physicians recommends that pharmacologic agents, including acetazolamide, lack sufficient evidence for routine prescription as primary OSA treatment, with weight loss and CPAP being first-line therapies 8